BPC-157 vs TB-500: how to stack them
BPC-157 vs TB-500 — different mechanisms, different best-use cases, and why the two together are the most-reported recovery stack.
Updated May 7, 2026 · 3 min read
BPC-157 and TB-500 are often discussed together but they're not interchangeable. They work through different mechanisms, fit different use cases, and pair well precisely because they don't overlap.
The short answer
| Use case | Best fit |
|---|---|
| Acute, well-localized soft-tissue injury | BPC-157 alone |
| Chronic tendinopathy, multiple overlapping issues | Stack both |
| Whole-body recovery from accumulated training damage | TB-500 alone or stack |
| Gut / GI focus | BPC-157 alone |
| Limited budget, only one peptide | BPC-157 (broader use case, cheaper, more research) |
The mechanism difference
This is what makes the stack rationale work:
| Property | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | Local angiogenesis, growth-factor upregulation | Actin sequestration, cell migration |
| Best route | SubQ near injury site (or systemic) | SubQ systemic |
| Half-life | Short (hours) | Long (days) |
| Dosing cadence | Daily | Twice weekly loading, then every 1–2 weeks |
| Pre-clinical strength | Tendon, gut, brain | Muscle, cardiac, corneal |
| Best for | Targeted injury, local healing | Systemic recovery, hard-to-localize injuries |
BPC-157 is the local artist — angiogenesis at the site, growth factors recruited, tissue repair driven where you put it. TB-500 is the dispatcher — actin reorganized, cells migrated, healing capacity distributed across tissue.
When BPC-157 alone is enough
For most acute, localized injuries:
- Pulled hamstring
- Sprained ankle
- Recent rotator-cuff strain
- A specific spot of GI inflammation
- Post-surgical recovery (if cleared by your surgeon)
Daily SubQ near the site, 4–6 weeks. The single-peptide protocol is cheaper, simpler, and reportedly sufficient for the majority of well-defined acute injuries.
When TB-500 alone makes sense
Less common, but it fits when the issue is systemic or hard to localize:
- Post-overtraining recovery where everything aches
- Recurring small injuries across multiple sites
- Recovery between heavy training blocks
Loading-phase TB-500 on its own can shift the recovery baseline without the daily-injection cadence BPC-157 demands.
When the stack earns its cost
The stack is most reported for:
- Chronic tendinopathy that hasn't healed in 6+ weeks of rest and PT
- Achilles, patellar, rotator-cuff, or elbow issues that recur after PT sessions
- Multiple overlapping injuries that are hard to address one at a time
- Cases where someone has run BPC-157 alone for 4 weeks with partial improvement
Reported stack protocol:
| Compound | Dose | Cadence |
|---|---|---|
| BPC-157 | 250 mcg | Daily SubQ near affected tissue |
| TB-500 | 2.5–5 mg | Twice weekly SubQ (loading), then every 1–2 weeks |
Total cycle 6–8 weeks. Reassess and discontinue or maintain as needed.
Cost reality
A typical BPC-157-only cycle (5 mg vial × 2 = 10 mg) at research-chem prices runs $80–150. A stacked cycle adds 4–6 vials of TB-500 (roughly $200–400), pushing the total to $300–550 for the cycle. If you only need one, BPC-157 is the higher-leverage choice for the budget.
Side-effect overlap
Running both doesn't double the side-effect risk, but it doesn't halve it either. The most-reported overlapping effects are:
- Lethargy in the first week (more pronounced with the loading phase of TB-500)
- Mild headaches
- Injection-site reactions (more sites, more chances)
The more consequential consideration is that both peptides promote angiogenesis and tissue regeneration. The cancer-related cautions in our side-effects pillar apply to either alone and to the stack.
A reasonable decision tree
- Localized acute injury, recent (under 6 weeks)? → BPC-157 alone, 4–6 weeks.
- Chronic tendinopathy or recurring injury? → BPC-157 alone first, 4 weeks. If only partial improvement, add TB-500 loading.
- Whole-body recovery focus, no specific injury? → TB-500 loading phase, BPC-157 optional.
- Active or recent cancer, family history of malignancy, or cardiovascular concerns? → Talk to a clinician first. Neither peptide is a free option.